Adma Biologics reported $193.58M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Adma Biologics USD 193.58M 124.25M Mar/2026
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Novavax USD 246.3M 200K Dec/2025
Omeros USD 403.72M 27.2M Jun/2024
Takeda JPY 4.37T 99.51B Mar/2026